Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
5Customers
2Debt Items
5Related Chains
Source-Backed Evidence Depth
Erasca, Inc. (ERAS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
2Distinct source URLs
7High confidence
0.775Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Erasca, Inc. Suppliers
Ticker
Name
Confidence
Evidence
GUANGZHOU-JOYO-PHARMATECH-CO-LTD
GUANGZHOU-JOYO-PHARMATECH-CO-LTD
90%
In May 2024, the Company entered into an exclusive license agreement (the Joyo License Agreement) with Guangzhou Joyo Pharmatech Co., Ltd. (Joyo) under which the Company was granted an exclusive, wor…
MEDSHINE-DISCOVERY-INC
MEDSHINE-DISCOVERY-INC
90%
In May 2024, the Company entered into an exclusive license agreement (the Medshine License Agreement) with Medshine Discovery Inc. (Medshine) under which the Company was granted an exclusive, worldwi…
the Company’s ability to successfully defend against allegations raised by, or any future litigation initiated by, Revolution Medicines (RevMed) that ERAS-0015 infringes patents held by RevMed
Reciprocal relationship from RVMD graph: Reciprocal relationship from ERAS graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from ERAS graph: Reciprocal relationship from RVMD g…
Erasca, Inc. Customers
Ticker
Name
Confidence
Evidence
ASANA-BIOSCIENCES-LLC
ASANA-BIOSCIENCES-LLC
62%
wholly-owned Australian subsidiary, Erasca Australia Pty Ltd (Erasca Australia), in order to conduct clinical activities in Australia for its development candidates. In November 2020, the Company ent…
ASN-PRODUCT-DEVELOPMENT-INC
ASN-PRODUCT-DEVELOPMENT-INC
62%
wholly-owned Australian subsidiary, Erasca Australia Pty Ltd (Erasca Australia), in order to conduct clinical activities in Australia for its development candidates. In November 2020, the Company ent…
ERASCA-AUSTRALIA-PTY-LTD
ERASCA-AUSTRALIA-PTY-LTD
62%
wholly-owned Australian subsidiary, Erasca Australia Pty Ltd (Erasca Australia), in order to conduct clinical activities in Australia for its development candidates. In November 2020, the Company ent…
ERASCA-VENTURES-LLC
ERASCA-VENTURES-LLC
62%
wholly-owned Australian subsidiary, Erasca Australia Pty Ltd (Erasca Australia), in order to conduct clinical activities in Australia for its development candidates. In November 2020, the Company ent…
GUANGZHOU-JOYO-PHARMATECH-CO-LTD
GUANGZHOU-JOYO-PHARMATECH-CO-LTD
62%
marketable securities on the condensed consolidated balance sheets. The carrying amounts of the Company’s financial instruments, including cash, prepaid expenses and other current assets, accounts pa…
Erasca, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ERAS-DEBT
Debt stack $46.0M
90%
Market cache reports total debt of $46.0M.
ERAS-DEBT-9347
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
Erasca, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Erasca, Inc..
Erasca, Inc. Ownership
Holder
Name
Confidence
Evidence
ERAS-OWNER-FRAZIER-LIFE-SCIENCES-MANAGEMENT
Frazier Life Sciences Management, L.P.
90%
13F overlay lists Frazier Life Sciences Management, L.P. as top holder; 226 tracked holders.
